Sanofi-Aventis Presents Positive Data From Atrial Fibrillation Trial
French pharmaceutical group Sanofi-Aventis has reported new positive data from the Athena trial which showed that dronedarone significantly reduced the incidence and total duration of hospital stays among patients with atrial fibrillation or atrial flutter.
In this new analysis, dronedarone significantly reduced the total number of hospital days by 28% (p
In addition to the demonstrated reduction of atrial fibrillation (AF)-related hospitalization by 37% (p
A second post-hoc analysis from Athena, also confirmed the rhythm and rate controlling properties of dronedarone, already previously demonstrated in lower risk populations studied in the Euridis, Adonis and Erato trials. This analysis showed that dronedarone reduced the incidence of first AF recurrence by 25% in patients in sinus rhythm at study initiation (p
According to the company, dronedarone also decreased mean heart rate during atrial fibrillation to 78 beats per minute, compared with 87 for placebo (p
In the Athena trial, compared to placebo, dronedarone showed a low risk of pro-arrhythmia and no excess of hospitalizations for congestive heart failure, the company said.